Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Pairing with alternating electric fields
What ifWhat if the regimen paired one active agent with alternating electric fields?
Claim language“combined with at least a second active agent”
Insulated electrode arrays on the scalp deliver intermediate-frequency alternating electric fields while the patient receives the drug on a separate schedule. The fields interfere with mitosis in dividing tumor cells.
1.2Additive tumor growth suppression
What ifWhat if the combined response matched the predicted additive response?
Claim language“a synergistic effect”
Each agent contributes to tumor growth suppression, and the regimen targets a predefined reduction in growth. Matched single-agent and combination groups provide the tumor-volume data for comparing the observed combination response with a prespecified additivity model.
1.3DNA methylation as primary insult
What ifWhat if the first active agent were a DNA-methylating compound?
Claim language“first active agent is VAL-083 (dianhydrodulcitol)”
An orally administered imidazotetrazine decomposes at physiological pH and generates a methylating species that modifies DNA bases. In cells with low repair activity for O6-methylguanine, replication across that lesion triggers mismatch repair and contributes to cell death.
1.3Blockade of DNA break repair
What ifWhat if the second active agent inhibited a kinase required for DNA double-strand break repair?
Claim language“a Bcl-2 family inhibitor”
A small-molecule inhibitor blocks the catalytic subunit of DNA-dependent protein kinase and reduces repair through classical nonhomologous end joining. The inhibitor is present when processing of the first agent's DNA cross-links generates double-strand breaks.
1.3Replication stress checkpoint blockade
What ifWhat if the second active agent blocked the replication stress checkpoint?
Claim language“a Bcl-2 family inhibitor”
A small-molecule inhibitor blocks the kinase that signals from stalled replication forks to checkpoint kinase 1. Weaker checkpoint signaling makes fork collapse more likely when replication encounters DNA cross-links.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Component substitution
Selective inhibition of the MCL1 protein
An MCL1-selective small molecule such as S63845 serves as the second active agent in a glioma cell assay. The assay pairs graded concentrations of the inhibitor with dianhydrodulcitol and includes wells for each agent alone at matching concentrations. A caspase activity assay measures apoptosis, and a separate viable-cell count measures the overall response.
Specific version of a part
Separate intravenous and oral formulations
A sterile aqueous infusion delivers the first active agent, and an immediate-release oral tablet delivers the second. The administration schedule aligns systemic exposure during a defined interval of each treatment cycle.
Synergy measured by tumor volume
A dose-matched study uses a control group, two single-agent groups, and a combination group. Serial magnetic resonance scans measure tumor volume, and the analysis identifies synergy when the observed combination response exceeds the prediction from a prespecified additivity model.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1the administration to said subject of a first active agent combined with at least a second active agent
The invention additionally provides a method for the treatment or prophylaxis of a cardiovascular disorder in a patient, which comprises treating the patient with a therapeutically effective amount of a combination of (a) a thioester or prodrug (preferably of formula I) that forms S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]thiol in vivo, and (b) at least one esterase inhibitor.
B · US 2016/0074360 A1 · ¶ 9
1.2wherein the combination of said first and said at least second active agent, when administered to a subject, results in a synergistic effect
Yet another aspect of the invention is an improvement in the therapeutic employment of an alkylating hexitol derivative for treatment of a TKI-resistant malignancy made by exploiting unique drug combinations that may provide a more than additive or synergistic improvement in efficacy or side-effect management.
A · US 2015/0182490 A1 · ¶ 234
1.3wherein said first active agent is VAL-083 (dianhydrodulcitol) and said at least second active agent is a Bcl-2 family inhibitor.
(bi) use with inhibitors of Bcl-2 or Bcl-xL;
A · US 2015/0182490 A1 · ¶ 449
An empty cell means only that no passage was reproduced there.
Statements in these documents
Therefore, there is an urgent need for therapeutic methods and pharmaceutical compositions that can treat malignancies in patients resistant to TKI chemotherapy.
A · US 2015/0182490 A1 · ¶ 5
Therefore, there is an urgent need for improved methods to treat malignancies associated with mutation or dysregulation of the AHI1 gene, particularly leukemias.
A · US 2015/0182490 A1 · ¶ 7
Some esterases can also split thioesters into acids and thiols, especially in the gastrointestinal tract, where degradation, formation of disulfide, or oxidation of the resulting thiol can occur before reaching the systemic circulation—thereby decreasing the bioavailability of any such thioester or thiol therapeutic agent.
B · US 2016/0074360 A1 · ¶ 2
In a first aspect the present invention provides a method for increasing the bioavailability of a thioester, wherein a dosage form containing an esterase inhibitor is administered (i.e., orally) in combination with a dosage form containing the thioester.
B · US 2016/0074360 A1 · ¶ 3
Cite aspatent.fyi, US 2026/0355145 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355145/, SHA-256 af0ccc8131563244b6c6fd7d6bcc7e9be660b11654e137c1061097261c32d839